Latest Biotech News

Continuous bioprocessing technologies, such as the XCell ATF system adopted by Enzene Biosciences, are improving monoclonal antibody manufacturing by enabling higher productivity, reduced costs,...

ProKidney's autologous cell therapy rilparencel demonstrated a significant reduction in kidney function decline by 78% in one cohort of diabetic chronic kidney disease patients. Another cohort...

Following disappointing clinical trial results with its KIT-targeting antibody briquilimab, Jasper Therapeutics is reducing its staff by approximately 50%. The clinical failures included loss of...

Radiopharmaceutical biotech Actithera closed a $75.5 million Series A round, despite operating as a single-person company during fundraising. The financing will support clinical development of...

Quanterix completed the acquisition of Akoya Biosciences for $127 million, integrating spatial biology and tissue testing technologies to streamline liquid biopsy biomarker discovery and...

Researchers led by Sofiane Bendifallah developed a non-invasive diagnostic approach for endometriosis using salivary microRNA signatures. This method may overcome the diagnostic delay associated...

Merck & Co. has agreed to acquire London-based Verona Pharma for approximately $10 billion, marking its largest deal since 2023. Verona's FDA-approved inhaled drug Ohtuvayre (ensifentrine) is...

Researchers at the University of Chicago developed a new liquid biopsy test detecting colorectal cancer through methylation modifications in microbiome-derived cell-free RNA in plasma. Utilizing...

Biopharmaceutical manufacturers are increasingly adopting continuous manufacturing techniques over traditional fed-batch methods for monoclonal antibody (mAb) production. Studies demonstrate...

ProKidney Corp. reported mixed data from its Phase II REGEN-007 trial evaluating rilparencel, a cell therapy for chronic kidney disease (CKD) in diabetic patients. In the two-dose cohort,...

Arvinas announced CEO John Houston will retire after over eight years steering the company, as its lead PROTAC (proteolysis-targeting chimera) protein degrader program nears a critical development...

Radiopharmaceutical developer Actithera closed a $75.5 million Series A financing round to advance clinical development of small-molecule therapeutics targeting fibroblast activation protein...

The FDA granted approval for a modified dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla to reduce risk of brain swelling, aiming to increase physician adoption. Meanwhile, Dizal...

The biopharma sector experienced a sharp rise in workforce reductions during the first half of 2025, with 128 reported layoff rounds—32% more than the same period last year. Multiple companies...

Iambic Therapeutics and Revolution Medicines entered a multi-year partnership integrating Iambic's AI-driven NeuralPLexer platform with Revolution’s proprietary oncology data. The collaboration...

Merck & Co. has agreed to acquire London-based Verona Pharma for $10 billion, securing the rights to Ohtuvayre, a lung drug recently approved by the FDA for chronic obstructive pulmonary disease...

The FDA granted approval for Eli Lilly’s revised dosing regimen of Alzheimer’s drug Kisunla to reduce the risk of brain swelling, addressing safety concerns that had limited its adoption....

ProKidney Corp. reported encouraging Phase II trial results for its cell therapy rilparencel in chronic kidney disease patients, showing a 78% slowing of kidney function decline in the two-dose...

Partnerships and technology developments are advancing AI-driven drug discovery and protein engineering. Revolution Medicines and Iambic Therapeutics formed a multi-year collaboration leveraging...

Layoffs in the biopharma sector surged 32% year-over-year in the first half of 2025, marking an all-time high for monthly reduction-in-force rounds, with 29 reported in May alone. Several biotechs...